Novo Nordisk expands research collaboration in novel delivery technologies for biologic medicines

Bagsværd, Denmark, 9 March 2022 – Novo Nordisk today announced the expansion of its existing research collaboration in oral drug delivery technologies with the Massachusetts Institute of Technology (MIT) and Brigham and Women’s Hospital (BWH).

Since 2015, scientists from Novo Nordisk and the laboratories of Prof. Giovanni Traverso and Prof. Robert Langer have explored novel technologies as alternatives to syringes and pen injectors, by co-creating new devices that safely and effectively deliver biologic medicines through oral administration. This collaboration has resulted in several high-impact scientific publications describing breakthrough inventions, including the SOMA robotic pill, which has subsequently been licensed exclusively to Novo Nordisk for clinical development.

“Working with the Langer and Traverso teams continues to be a unique opportunity for Novo Nordisk to live out our aspiration of bringing transformational new solutions to patients by thinking big, working with the best, and using our distinct capabilities to aim to achieve what might otherwise seem impossible,” said Marcus Schindler, PhD, professor, executive vice president and chief scientific officer of Novo Nordisk.

The new agreement extends the collaboration through 2026, expanding the scope to encompass the creation and integration of bioelectronics, biosensors and stimuli-responsive delivery devices.

“We continue to explore the immense potential for enhanced delivery of biologic drugs and stem cell-derived therapeutics through the platforms we are developing,” said Giovanni Traverso, the Karl van Tassel, Career Development Assistant Professor of Mechanical Engineering at MIT and a gastroenterologist at Brigham and Women’s Hospital, Harvard Medical School.

“Our group at MIT strives to combine engineering and medicine to solve important problems and find the best ways to get those solutions to the people who need them,” added Robert Langer, David H. Koch Institute Professor at MIT. “Our work together with Novo Nordisk has shown that they share this vision, and we are thrilled to expand into this ambitious new program together”.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 47,800 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube.

Further information

Media:
Martin Havtorn Petersen	+45 3075 5246	mhpz@novonordisk.com
Michael Bachner (US)	+1 609 664 7308	mzyb@novonordisk.com
Investors:
Daniel Muusmann Bohsen	+45 3075 2175	dabo@novonordisk.com
Ann Søndermølle Rendbæk	+45 3075 2253	arnd@novonordisk.com
David Heiberg Landsted	+45 3077 6915	dhel@novonordisk.com
Jacob Martin Wiborg Rode	+45 3075 5956	jrde@novonordisk.com
Mark Joseph Root (US)	+1 848 213 3219	mjhr@novonordisk.com

Attachment

• PR220309_MIT_NN_expansion